Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Cancer community members will join the Turing network for 2021-2022 to further their research in cancer big data.

Binary code

The Alan Turing Institute is the national institute for data science and artificial intelligence. Turing researchers are based in universities and centres of research excellence across the UK and undertake interdisciplinary research of relevance to real-world problems. This month, the Institute welcomed 400 new outstanding fellows from across the academic spectrum.

This includes 4 Oxford Cancer community members for the 2021-2022 Fellowship, whose work have applications in cancer science. Those joining the Turing’s vibrant, interdisciplinary, and collaborative research community are:

  • Hashem Koohy (MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine)
  • Rafael Perera (Nuffield Department of Primary Care Health Sciences)
  • Benjamin Schuster-Böckler (Ludwig Institute for Cancer Research, Nuffield Department of Medicine).
  • Clare Verrill (Nuffield Department of Surgical Sciences)

 

It gives me great pleasure to welcome this new group of Fellows. This cohort is incredibly multidisciplinary and diverse. They will bring a rich range of expertise and ensure we continue to do world-leading, impactful research.
-  Adrian Smith, Turing Institute Director and Chief Executive. 

Turing Fellows are ‘mid-to-senior career’ scholars with proven research excellence in data science, artificial intelligence, or a related field, whose research would be significantly enhanced through active involvement with the Turing network of universities and partners. The University of Oxford is one of the founding University partners and is eligible to nominate up to 35 fellows a year.

 

Congratulations to the new fellows!

Similar Stories

Automated assessment of pathology image quality

The new Oxford-developed artificial intelligence tool PathProfiler automates the quality control of large retrospective pathology image datasets to increase their usability in downstream research.

Oxford spin-out Optellum attains CE marking for its early lung cancer diagnosis AI technology

Optellum Virtual Nodule Clinic, including its proprietary artificial intelligence lung cancer prediction solution, has achieved CE certification under the European Union’s Medical Device Regulation.

Adiposity in early life, but not adulthood, may protect against breast cancer

New data from the Million Women Study indicates that adiposity at different life stages is likely to affect the risk of postmenopausal breast cancer through distinct mechanisms.